Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inhibrx Inc (NQ: INBX )

22.39 +1.62 (+7.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,479
Open 20.65
Bid (Size) 17.50 (1)
Ask (Size) 22.62 (58)
Prev. Close 20.77
Today's Range 19.86 - 22.44
52wk Range 14.30 - 32.71
Shares Outstanding 37,892,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property

Performance

YTD
-3.91%
-3.91%
1 Month
+41.80%
+41.80%
3 Month
-0.71%
-0.71%
6 Month
-8.98%
-8.98%
1 Year
-25.98%
-25.98%

More News

Read More
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
Via Benzinga
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
Via Benzinga
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
Via Investor's Business Daily
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Why Is Inhibrx (INBX) Stock Soaring 45% Today?
Via InvestorPlace
Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge
Via Benzinga
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
Via Benzinga
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
Via Benzinga
Stocks Reverse Gains After ADP Report
Via Talk Markets
S&P 500 Rises 100 Points; Nasdaq Up 3%
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Via FinancialNewsMedia
Topics Death
Exposures Death
Nasdaq Surges 350 Points; Crude Oil Rises Sharply
Via Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
US Stocks Open Higher As Dow Jumps 550 Points
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Via Benzinga
Inhibrx Secures European Commission Orphan Medicinal Product Designation For Bone Cancer Candidate
Via Benzinga
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
73 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.